Tangying Lu
Overview
Explore the profile of Tangying Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu Y, Parker L, Lu T, Zheng Z, Toomey M, White D, et al.
J Clin Oncol
. 2017 Aug;
35(29):3322-3329.
PMID: 28809608
Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for patients with metastatic cancer. Most current strategies use genes that encode major histocompatibility complex (MHC)...
2.
Kochenderfer J, Somerville R, Lu T, Yang J, Sherry R, Feldman S, et al.
Mol Ther
. 2017 Aug;
25(10):2245-2253.
PMID: 28803861
T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term durability of these remissions is unknown. We administered...
3.
Kochenderfer J, Somerville R, Lu T, Shi V, Bot A, Rossi J, et al.
J Clin Oncol
. 2017 Mar;
35(16):1803-1813.
PMID: 28291388
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19...
4.
Lu T, Gabrilovich D
Clin Cancer Res
. 2012 Jun;
18(18):4877-82.
PMID: 22718858
Tumor-associated myeloid cells are the major type of inflammatory cells involved in the regulation of antitumor immune responses. One key characteristic of these cells is the generation of reactive oxygen...
5.
Lu T, Ramakrishnan R, Altiok S, Youn J, Cheng P, Celis E, et al.
J Clin Invest
. 2011 Sep;
121(10):4015-29.
PMID: 21911941
Cancer immunotherapeutic approaches induce tumor-specific immune responses, in particular CTL responses, in many patients treated. However, such approaches are clinically beneficial to only a few patients. We set out to...
6.
Lu T, Newton C, Perkins I, Friedman H, Klein T
J Pharmacol Exp Ther
. 2006 Jul;
319(1):269-76.
PMID: 16837556
Marijuana cannabinoids, such as delta-9-tetrahydrocannabinoid (THC), suppress type 1 T-helper 1 (Th1) immunity in a variety of models, including infection with the intracellular pathogen Legionella pneumophila (Lp). To examine the...
7.
Lu T, Newton C, Perkins I, Friedman H, Klein T
Eur J Pharmacol
. 2006 Jan;
532(1-2):170-7.
PMID: 16443217
Delta-9-tetrahydrocannabinol (THC) injection suppresses serum interleukin-12 (IL-12) levels in Legionella pneumophila-infected mice. Dendritic cells are a major producer of IL-12 and mouse, bone marrow-derived dendritic cell cultures produced high levels...
8.
Newton C, Lu T, Nazian S, Perkins I, Friedman H, Klein T
J Leukoc Biol
. 2004 Jul;
76(4):854-61.
PMID: 15258190
T helper cell type 1 (Th1)-polarizing cytokines are induced by Legionella pneumophila infection and are suppressed by pretreatment with marijuana cannabinoids (CB). Glucocorticoids and prostaglandin E2(PGE2) are also reported to...